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Abstract 
There are about 150 million carriers of hepatitis B virus all over the world, most of whom are unaware that they 
are carriers. Most babies born to mothers who are carriers also become carriers. About 25% of untreated babies 
who are infected with hepatitis B virus subsequently develop severe chronic liver disease or even liver cancer. 
Hepatitis B kills about 1.1 million people annually. It can be prevented through a safe and effective hepatitis B 
vaccine. This vaccine has been introduced in Albanian Immunization Program nationwide in 1994. Hepatitis B 
is given at birth followed by three doses at 2, 4 and 6 months where Hepatitis B is included in DTP-HepB-Hib 
vaccine. The aim of this study was to evaluate Immunization Program with Hepatitis B vaccination in order to 
prove program efficacy, increase public confidence in immunizations and advocate for sustainable 
immunization programs. Methodology was based on three components such as Immunization coverage surveys, 
serologic surveys and surveillance for acute cases of Hepatitis B. Results of this study showed that vaccination 
coverage is really high, more than 95% and with drop-out rates less than 10%. Anti-HBs levels in immunized 
children are very high comparing to unimmunized ones. Incidence of Hepatitis B in children 0-14 years old is 
almost zero. Such results tell us that vaccination with Hepatitis B is one of the most fruitful strategies on long 
term control of Hepatitis B in a country with a high HBV endemicity like ours. 
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1.  Introduction 
Hepatitis B (HepB) is a major public health 
problem worldwide. Approximately 30% of the 
world’s population, or about 2 billion persons, have 
serologic evidence of hepatitis B virus (HBV) 
infection. Of these, an estimated 350 million have 
chronic HBV infection and at least one million 
chronically infected persons die each year from liver 
cancer and cirrhosis. HBV is second only to tobacco 
as a known human carcinogen. 
A safe and effective vaccine against HepB has 
been available for nearly 20 years. HepB vaccine is 
effective in preventing HBV infections when it is 
given either before exposure or shortly after exposure. 
At least 85%-90% of HBV-associated deaths are 
vaccine-preventable.[8, 9] 
Even Immunization Program in Albania started 
in 1993; health sector has been producing vaccines 
such as Bacillus Calmette Guerin (BCG), Diphtheria 
Tetanus Pertussis (DTP) and Measles except the one 
of live oral polio (OPV) which has been imported. In 
1994 Ministry of Health introduced for the first time 
Hepatitis B vaccine for all newborn babies. Actual 
Albanian immunization schedule for Hepatitis B is: 
one dose at birth (called protection dose) followed by 
three doses at 2, 4 and 6 months where Hepatitis B is 
included in DTP-HepB-Hib vaccine. 
The aim of the study was evaluation of 
Immunization Program with Hepatitis B vaccine  in 
order to prove that what we are doing is working: 
Immunization  →Decreased incidence and mortality; 
increase public confidence in immunizations and 
advocate for sustainable immunization programs. 
2.  Material and methods 
Methodology used, was based on three main 
components: 
1)  Immunization coverage surveys. Most 
immunization coverage surveys are based on data that 
are routinely collected during immunizations, making 
these an inexpensive way to gather information. 
Coverage surveys can provide data on how many 
people initiate hepatitis B vaccination; how many 
complete all three doses; and how many babies 
receive the birth dose. It can also allow comparisons 
of hepatitis B immunization coverage rates with those 
of more established vaccines such as DTP.[1],[3, 10] 
Our study was based on surveys of Hepatitis B 
vaccine indicators included in routine immunization 
coverage through the years 1995-2012 Nelaj et al 
2)  Serologic surveys. Serologic surveys can 
provide a more direct measure of the impact of an 
immunization program by comparing the prevalence 
of infection before and after the program is 
implemented. Serologic surveys typically measure 
HBsAg (present in those with chronic infection) and 
antibody to hepatitis B core antigen (anti-HBc) 
(present in those who have been infected in the past or 
are chronically infected).[4, 11] 
The aim was to compare sero-prevalence of 
infection in target population (0-14 yrs and >14 yrs) 
before & after commencement of immunization 
program. [5, 6] 
3) Surveillance for acute cases of hepatitis B. 
This type of disease surveillance is useful in countries 
in which there is a high incidence of acute hepatitis B 
cases like our country. Acute disease surveillance 
requires a standardized case definition that includes 
clinical and laboratory components, and a strategy for 
identifying ill persons. In our country we do not have 
sufficient laboratory diagnostic capacity to distinguish 
among types of viral hepatitis, so in our system of 
reporting diseases (14Sh - form) acute viral hepatitis 
are unspecified ones.[2] 
We based our study on incidence of Acute Viral 
Hepatitis (unspecified), in 0-14 years old children, 
during 2000-2012. 
3.  Results and Discussion  
Results on this study are presented according to 
each specific objective and their indicators as they 
were designed on the methodology part. 
•  Indicators for immunization coverage: Percentage 
of immunization coverage for each indicator of 
HepB vaccination (% of HepB1, HepB2, HepB3, 
Drop out of HepB1-HepB3 and Drop out HepB3-
DTP3) [1, 10] 
•  Limitations: Coverage surveys do not provide a 
direct measure of the impact of vaccination on 
disease burden. Although high vaccine coverage 
often correlates with decreased disease burden, it 
is possible to have high coverage and low vaccine 
efficiency (e.g., if frozen vaccine is used, the 
vaccine is not administered properly, or the 
vaccine is administered after infection occurs [i.e., 
perinatal infection]).[12, 13] 
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Figure 1: Third dose of Hepatitis B vaccination coverage through years 
As we can see from this graph national 
vaccination coverage is over than 95% through the 
years, reaching sometimes the level of 99%. The 
coverage level more than 95% is also reached by most 
of the districts in Albania.  
Also, drop out rate is an indicator which tells us 
the level of unfinished immunization schedule. 
According to WHO recommendations it should not be 
more than 10%. Through years drop out is not more 
than 10% in country level. Regarding to the 
drop out values for each district there are 
some with more than 10% rate but this levels 
are decreased by years. 
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The internal migration was one of the main 
factors affecting this rate and it seems to be stabilized 
in the last years.  
Another indicator which reflects the 
establishment of Hepatitis B vaccine in the national 
schedule is its comparison with DTP vaccine (a very 
well establish vaccine). [14] It results to be very well 
established from 2000  till 2008 and it continue to be 
in the same level as DTP now days since they are 
given in a combined vaccine DTP-HepB-Hib. 
 
Figure 2: Percentage of district level’s drop out rates for HepB3 versus HepB1 doses through years 
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Figure 3. Vaccination coverage of Hepatitis B third dose compared with the third dose of DTP 
Indicators for serologic surveys: Prevalence of 
serologic markers in these target  
population, through studies done at Virology-
Immunology Laboratory in the Institute of Public 
Health, during these years.  
Table 1.Prevalence of Hepatitis B marker’s 
vaccinated and not vaccinated children. 
Prevalence of Hepatitis B marker’s  
 Age group  HBsAg  + Anti  HBs Anti  HBc 
0-14 years  1,40% 71,80% 8,50% 
>14 years  15,3% 54,60%  56% 
Table 2.Prevalence of Hepatitis B marker’s 
in different age groups 
Prevalence of HBsAg 
   Serume HBsAg  + HBsAg  +  (%) 
Total  806 157  20,7% 
0-14 vjec  409 33  8,7% 
>14 vjec  397 124  31,2% 
Anti-HBs prevalence is much higher in 
vaccinated children than in the not vaccinated ones, as 
well as HbsAg+ prevalence is much lower in 0-14 yrs 
old children in comparison with >14 yrs old ones.  
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Indicator regarding surveillance of acute viral 
Hepatitis B: Incidence of new cases with Acute Viral 
Hepatitis in 100,000 habitants per year. [7] 
 
Figure 3. Incidence of unspecified viral hepatitis compared with vaccination coverage through years. 
As we can see, from this graph, unspecified acute 
Viral Hepatitis incidence is decreasing with years 
while vaccination coverage continue to be at high 
levels all the time. 
4.  Conclusion 
•  Vaccination coverage is over than 95% in 
country and districts levels. Drop out is not more 
than 10% in country level. Regarding to the drop 
out values more than 10% in some districts 
levels they are decreased by years. Hepatitis B 
vaccine was as well establish as DTP vaccine, 
till 2008 and it continue to be in the same level 
as DTP now days since they are given in a 
combined vaccine DTP-HepB-Hib. 
•  Anti-HBs prevalence is much higher in 
vaccinated children than in the not vaccinated 
ones, as well as HBsAg prevalence is much 
lower in 0-14 yrs old children in comparison 
with >14 yrs old ones.  
•  Acute Viral Hepatitis incidence is decreasing 
with years. 
•  On the basis of vaccination coverage data, sero-
survey results and epidemiological surveillance 
data, the national policy of mandatory 
vaccination of infants against hepatitis B is 
instituted (from 1994 onwards) in Albania, as 
the most fruitful strategy for long term control 
of hepatitis B in a country with a high HBV 
endemicity. 
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